German Startup Cracks the Code to Lab-Made Breast Milk Sugars
Leipzig-based startup Primogene has developed a way to produce human milk sugars (HMOs) on a large scale. The company uses biotechnology to create complex, bioidentical molecules that mimic those found in breast milk. Its work has already attracted funding and industry recognition.
Primogene specialises in biotech production of compounds identical to those in nature. Its core focus is human milk oligosaccharides (HMOs), the third-most abundant solid component in breast milk. These sugars are known for their unique health benefits, particularly in supporting infant development and immune function.
The company's proprietary technology allows it to manufacture HMOs efficiently. Current research, conducted with the Fraunhofer Institute for Cell Therapy and Immunology in Leipzig, is exploring their use in preventing necrotizing enterocolitis (NEC) in premature babies. Studies are also investigating how these sugars could shape the gut microbiome to reduce infections in infants. Preclinical and early clinical trials are underway as of 2025.
Beyond infant nutrition, Primogene is examining HMOs for disease prevention in adults. The startup also produces bioidentical molecules for other markets, including skincare ingredients and pharmaceutical raw materials. Early revenue has come from partnerships and pre-orders, with cosmetic products set to launch later this year.
Primogene has grown quickly, now employing a team of eleven. A recent move to a larger Leipzig facility supports its expansion plans. The company's progress has been boosted by funding from biotech investors, grants from the state of Saxony and the city of Leipzig, and increased visibility after winning the 2024 Saxon Founders' Award.
Primogene's technology could lead to new additives for premature infant nutrition and broader health applications. The company's work aligns with Saxony's reputation as an innovation hub, where initiatives like futureSAX help turn research into market-ready solutions. With ongoing studies and commercial partnerships, its products may soon reach wider use.
